Advertisement
U.S. markets close in 5 hours 16 minutes

ARGX Dec 2024 310.000 put

OPR - OPR Delayed Price. Currency in USD
12.960.00 (0.00%)
As of 09:04AM EST. Market open.
Full screen
Previous Close12.96
Open12.96
Bid0.10
Ask5.00
Strike310.00
Expire Date2024-12-20
Day's Range12.96 - 12.96
Contract RangeN/A
Volume6
Open Interest8
  • BioPharma Dive

    Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial

    Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target in sight and an FDA veteran plans retirement.

  • GlobeNewswire

    argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

    Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disease